NCT01312636View on ClinicalTrials.gov

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Congenital Bleeding DisorderCongenital FVII Deficiency
Interventions
DRUG

activated recombinant human factor VII

Data will be collected at the baseline visit and approximately once a year until end of study.

Trial Locations (1)

1000005

Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY